- Report
- October 2025
- 196 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 124 Pages
Global
From €2682EUR$2,999USD£2,326GBP
- Report
- January 2025
- 175 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- April 2025
- 200 Pages
Global
From €2227EUR$2,490USD£1,931GBP
- Report
- April 2025
- 200 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- March 2025
- 200 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- September 2023
- 180 Pages
Global
From €5321EUR$5,950USD£4,615GBP
- Report
- June 2024
- 200 Pages
Global
From €7110EUR$7,950USD£6,167GBP
- Report
- June 2022
- 320 Pages
Global
From €12431EUR$13,900USD£10,782GBP
- Report
- January 2024
- 206 Pages
Global
From €3980EUR$4,450USD£3,452GBP
- Report
- June 2023
- 280 Pages
Global
From €2236EUR$2,500USD£1,939GBP

Choroidal Neovascularization (CNV) is a condition in which abnormal blood vessels grow beneath the retina in the eye. It is a major cause of vision loss in age-related macular degeneration (AMD). Optical treatments for CNV include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to destroy the abnormal blood vessels and prevent further vision loss. Photodynamic therapy uses a light-activated drug to destroy the abnormal vessels. Anti-VEGF injections are used to block the growth of new vessels and reduce fluid leakage.
The CNV market is highly competitive, with a number of companies offering treatments and products. These include Novartis, Regeneron, Allergan, Roche, Bayer, and Santen Pharmaceuticals. Show Less Read more